Sermorelin Information & Coordination for Licensed U.S. Clinics
Sermorelin acetate is a synthetic peptide related to growth hormone-releasing hormone (GHRH) with a documented U.S. regulatory history.
Specific FDA-approved drug products containing sermorelin acetate were previously marketed under the brand name Geref. Those products were later discontinued, and FDA determined that they were not withdrawn for reasons of safety or effectiveness.
Phoenix Meds Inc. supports licensed U.S. healthcare organizations with clinic verification, documentation organization, publicly available regulatory information, and administrative pharmacy coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, wholesaler, distributor, or dispensing entity.
What Clinics Should Know About Sermorelin
Sermorelin acetate should not be treated as though every preparation containing the substance has the same regulatory status.
The former Geref products were specific FDA-approved drug products with defined strengths, labeling, and approved uses. That historical approval does not automatically extend to a current compounded preparation or another product marketed under the sermorelin name.
For that reason, clinics reviewing sermorelin-related information should distinguish the drug substance from the specific preparation, strength, labeling, dispensing pharmacy, and supporting documentation involved.
Phoenix Meds does not promote sermorelin for anti-aging, longevity, body-composition enhancement, recovery, metabolic optimization, or other unapproved treatment outcomes.
Current FDA and Compounding Status
FDA’s March 21, 2025 document lists sermorelin acetate in Category 1 – Bulk Drug Substances Under Evaluation for section 503B. FDA also identifies sermorelin acetate as a substance that has been a component of an FDA-approved drug.
Category 1 means FDA has sufficient nomination information to evaluate the substance and that it may be eligible for inclusion on the 503B Bulks List. It does not mean sermorelin acetate has been finally added to that list, does not make a compounded sermorelin preparation FDA-approved, and does not establish that a particular preparation qualifies under section 503B.
Product-specific compounding, dispensing, and regulatory determinations remain with the appropriately licensed pharmacy and other responsible professionals.
Why Product Identity Matters
A product described simply as “sermorelin” may differ from another preparation in formulation, concentration, excipients, labeling, storage information, and pharmacy documentation.
The name of the ingredient alone does not establish FDA approval, compounding eligibility, product quality, availability, or clinical suitability.
For professional review, clinics should therefore look at the documentation associated with the specific preparation rather than relying only on the ingredient name or historical Geref approval.
Phoenix Meds can help organize available records and publicly available regulatory information so relevant questions can be identified before they are referred to the appropriate licensed parties.
How Phoenix Meds Supports Licensed Clinics
Phoenix Meds helps licensed U.S. healthcare organizations manage the administrative work involved in clinic-pharmacy coordination.
For sermorelin-related inquiries, our support may include clinic credential verification, organization of available formulation and pharmacy documentation, access to publicly available regulatory information, and administrative communication with independent licensed pharmacies.
We can also help keep clinic onboarding, documentation follow-up, and pharmacy communication organized so clinic teams have a clearer administrative path before questions move to the licensed parties responsible for prescribing, compounding, dispensing, and patient care.
Phoenix Meds does not make clinical decisions, determine whether a preparation may be compounded, or certify pharmacy or product compliance.
Safety and Documentation Considerations
Relevant documentation may include formulation information, labeling, storage instructions, dispensing-pharmacy information, and supporting records supplied by the pharmacy.
Phoenix Meds may help organize those materials as part of the administrative coordination process.
We do not manufacture, test, compound, prescribe, dispense, ship, or take custody of sermorelin preparations. We also do not independently certify purity, potency, sterility, stability, authenticity, safety, or clinical suitability.
A Certificate of Analysis, pharmacy license, or facility registration should not by itself be presented as proof that a particular preparation is FDA-approved or qualifies under a particular compounding pathway.
Sermorelin Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds regarding clinic verification, documentation, and publicly available regulatory information relevant to a sermorelin-related professional inquiry.
Clinic Verification
Documentation Review
Licensed Parties
Frequently Asked Questions
Is sermorelin FDA-approved?
Specific sermorelin acetate products marketed under the brand name Geref were previously FDA-approved. Those products were later discontinued.
Historical approval of Geref does not mean that every current sermorelin preparation is FDA-approved.
Why does the former Geref approval matter?
It establishes an important part of sermorelin acetate’s U.S. regulatory history. FDA also determined that the discontinued Geref products were not withdrawn for reasons of safety or effectiveness.
That history should still be distinguished from the regulatory status of any current preparation.
How is sermorelin acetate currently listed in FDA’s 503B compounding materials?
Does Phoenix Meds determine whether a sermorelin preparation can be compounded or dispensed?
No. Those determinations remain with the appropriately licensed pharmacy and other professionals responsible for the preparation, prescription, and patient care.
Does Phoenix Meds test or certify sermorelin preparations?
No. Phoenix does not independently test or certify purity, potency, sterility, stability, authenticity, safety, or clinical suitability.
What can Phoenix Meds help a clinic with?
Our role is administrative and may include clinic credential verification, documentation organization, publicly available regulatory information, and administrative communication relating to clinic-pharmacy coordination.
Important Notice
Phoenix Meds Inc. provides administrative coordination and documentation support for licensed U.S. healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, wholesaler, distributor, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It is not medical advice, a prescribing recommendation, FDA approval, or a determination that a particular sermorelin preparation is available, eligible for compounding, or clinically appropriate.
Regulatory Resources
- FDA / Federal Register — Determination That Geref (Sermorelin Acetate) Was Not Withdrawn for Reasons of Safety or Effectiveness
- FDA — Sermorelin Acetate / Geref Orphan Drug Designation and Approval Record
- FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503B
- FDA — Bulk Drug Substances Used in Compounding Under Section 503B
- FDA — 503B Bulk Drug Substances List
- FDA — Compounding and FDA: Questions and Answers